-
Mashup Score: 114Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial - 3 month(s) ago
Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.
Source: ascopubs.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 32MYC targeting by OMO-103 in solid tumors: a phase 1 trial - 3 month(s) ago
Nature Medicine – In this first-in-human phase 1 dose-escalation trial of OMO-103, a MYC inhibitor, in patients with solid tumors, treatment was safe and showed preliminary clinical activity…
Source: www.nature.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 31MYC targeting by OMO-103 in solid tumors: a phase 1 trial - 3 month(s) ago
Nature Medicine – In this first-in-human phase 1 dose-escalation trial of OMO-103, a MYC inhibitor, in patients with solid tumors, treatment was safe and showed preliminary clinical activity…
Source: www.nature.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 30MYC targeting by OMO-103 in solid tumors: a phase 1 trial - 3 month(s) ago
Nature Medicine – In this first-in-human phase 1 dose-escalation trial of OMO-103, a MYC inhibitor, in patients with solid tumors, treatment was safe and showed preliminary clinical activity…
Source: www.nature.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 5Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in Cancer - 3 month(s) ago
“Just Accepted” papers have undergone full peer review and have been accepted for publication in Radiology: Artificial Intelligence. This article will undergo copyediting, layout, and proof review before it is published in its final version. Please note that during production of the final copyedited article, errors may be discovered which could affect the content. Purpose To identify precise 3D radiomics features in CT images that enable computation of stable and biologically meaningful habitats with machine learning for cancer heterogeneity assessment. Materials and Methods This retrospective study included 2436 liver or lung lesions from 605 CT scans (November 2010-December 2021) in 318 patients with cancer (mean age, 64.5 years ± 10.1 [SD]; 185 male patients). 3D radiomics were computed from original and perturbed (simulated retest) images with different combinations of feature computation kernel radius (R) and bin size (B). The lower 95% confidence limit (LCL) of the intraclass cor
Source: pubs.rsna.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 17Ref. 78-2023 Postdoctoral position at the Prostate Cancer Translational Research Group - 5 month(s) ago
The Vall d´Hebron Institute of Oncology (VHIO) Seeks a “Postdoctoral position at the Prostate Cancer Translational Research Group” Reference:…
Source: vhio.netCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 113Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial - 5 month(s) ago
Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.
Source: ascopubs.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 104Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial - 6 month(s) ago
Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.
Source: ascopubs.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 2Home Page: ESMO Real World Data and Digital Oncology - 7 month(s) ago
ESMO Real-World Data and Digital Oncology is the European Society for Medical Oncology’s latest peer-reviewed open access journal. It is dedicated to publishing high-quality data science and educational content on the transformation of oncology care with real-world evidence and digital technologies that physicians can trust and understand. The journal will publish innovative research that provides actionable insights from real-world data sources and digital devices, such as generalizable observational
Source: www.esmorwd.orgCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 3
www.soltihope.com, identifier NCT04497285.
Source: pubmed.ncbi.nlm.nih.govCategories: Latest Headlines, Oncologists2Tweet
Delving deep into outcomes for the BRCA+ population in PROFOUND, the pivotal Olaparib registration trial for #prostatecancer, our paper (with many++ collaborators) @JCO_ASCO https://t.co/bo8KbwXZfA https://t.co/QCGDSXxaww